IDEXX Laboratories Inc (IDXX)

Currency in USD
556.93
+11.07(+2.03%)
Closed·
556.930.00(0.00%)
·
IDXX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
544.88557.66
52 wk Range
518.55769.98
Key Statistics
Prev. Close
545.86
Open
550.14
Day's Range
544.88-557.66
52 wk Range
518.55-769.98
Volume
485.78K
Average Volume (3m)
652.68K
1-Year Change
-13.7278%
Book Value / Share
20.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IDXX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
698.92
Upside
+25.50%
Members' Sentiments
Bearish
Bullish
ProTips
Management has been aggressively buying back shares

IDEXX Laboratories Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

Analyst Ratings

8 Buy
5 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 698.92
(+25.50% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy675.00+21.20%-MaintainAug 20, 2026
Barclays
Buy710.00+27.48%800.00MaintainAug 11, 2026
UBS
Hold670.00+20.30%620.00MaintainAug 05, 2026
UBS
Hold620.00+11.32%640.00MaintainJul 27, 2026
BofA Securities
Hold660.00+18.51%790.00MaintainMay 05, 2026

IDEXX Laboratories Inc SWOT Analysis


Market Leadership
Explore IDEXX's dominance in veterinary diagnostics, balancing declining visits with increased utilization and innovative product launches
Financial Resilience
Despite market headwinds, IDEXX maintains robust profitability with a 60.7% gross margin and 7.2% revenue growth, showcasing its financial strength
Growth Projections
Analysts forecast sustainable double-digit top-line growth for IDEXX, with price targets ranging from $481 to $630, reflecting optimistic long-term outlook
Strategic Innovation
Delve into IDEXX's product development strategy, including the inVue Dx Analyzer and IDXX Cancer Dx, driving competitive advantage in a evolving market
Read full SWOT analysis

IDEXX Laboratories Inc Earnings Call Summary for Q2/2026

  • IDEXX Q2 profit hit $4.27/share on $1.22B revenue, topping estimates of $3.96/share and $1.20B; shares surged 6.8% to $606.44 in premarket trading.
  • Gross margin expanded 120bps to 64% driven by recurring diagnostics revenue growth of 10.3% and favorable product mix despite 1.3% U.S. clinic visit decline.
  • Company raised FY2026 guidance to $4.70B-$4.745B revenue and $14.69-$14.94 EPS, projecting 13%-15% comparable earnings growth and 8.5%-9.7% organic revenue growth.
  • Free cash flow reached $557M year-to-date with $693M in share repurchases; management maintains 90%-100% FCF conversion target and plans $180M capex for 2026.
  • InVue Dx fine-needle aspirate testing to reach broad availability by year-end; Cancer Dx expansion planned for late Q3 with mast cell tumor detection capabilities.
Last Updated: 2026-08-04, 09:54 a/m
Read Full Transcript

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
4.27 / 3.96
Revenue / Forecast
1.22B / 1.2B
EPS Revisions
Last 90 days

IDXX Income Statement

Compare IDXX to Peers and Sector

Metrics to compare
IDXX
Peers
Sector
Relationship
P/E Ratio
38.5x19.0x−0.4x
PEG Ratio
2.090.550.00
Price/Book
27.2x2.5x2.6x
Price / LTM Sales
9.6x1.8x3.1x
Upside (Analyst Target)
25.7%36.9%48.9%
Fair Value Upside
Unlock30.5%6.2%Unlock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
41.89M53.17%23.33B
Other Institutional Investors
34.56M43.86%19.25B
Public Companies & Retail Investors
2.34M2.97%1.30B
Total
78.78M100.00%43.88B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.10.37%8,170,1784,550,217
Vanguard Capital Management, LLC7.11%5,603,8763,120,967

People Also Watch

294.85
GRMN
+0.60%
124.48
PAYX
+1.27%
187.50
VRSK
-0.10%
229.07
PAYC
+1.04%
32.04
KDP
+1.20%

FAQ

What Is the IDEXX Labs (IDXX) Stock Price Today?

The IDEXX Labs stock price today is 556.93 USD.

What Stock Exchange Does IDEXX Labs Trade On?

IDEXX Labs is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for IDEXX Labs?

The stock symbol for IDEXX Labs is "IDXX."

What Is the IDEXX Labs Market Cap?

As of today, IDEXX Labs market cap is 43.88B USD.

What Is IDEXX Labs's Earnings Per Share (TTM)?

The IDEXX Labs EPS (TTM) is 14.22.

When Is the Next IDEXX Labs Earnings Date?

IDEXX Labs will release its next earnings report on Nov 03, 2026.

From a Technical Analysis Perspective, Is IDXX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IDEXX Labs Stock Split?

IDEXX Labs has split 4 times.

How Many Employees Does IDEXX Labs Have?

IDEXX Labs has 11000 employees.

What is the current trading status of IDEXX Labs (IDXX)?

As of Aug 23, 2026, IDEXX Labs (IDXX) is trading at a price of 556.93 USD, with a previous close of 545.86 USD. The stock has fluctuated within a day range of 544.88 USD to 557.66 USD, while its 52-week range spans from 518.55 USD to 769.98 USD.

What Is IDEXX Labs (IDXX) Price Target According to Analysts?

The average 12-month price target for IDEXX Labs is 698.92 USD, with a high estimate of 805 USD and a low estimate of 470 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +25.50% Upside potential.

What Is the IDXX Premarket Price?

IDXX's last pre-market stock price is 553.60 USD. The pre-market share volume is 310.00, and the stock has decreased by 7.74, or 1.42%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.